Endophthalmitis associated with intravitreal injections: Office-based setting and operating room setting

Homayoun Tabandeh, Francesco Boscia, Alessandra Sborgia, Lorenza Ciracì, Pouya Dayani, Cesare Mariotti, Claudio Furino, Harry W Flynn

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Purpose: To report on the occurrence of endophthalmitis after intravitreal injections (IVI) in two different settings: office-based and operating room. Methods: Consecutive case series. Retrospective review of all patients who underwent IVI by 2 physicians between January 2009 and December 2011. Group A underwent IVI in the examination room in office-based setting and Group B underwent IVI in the operating room. Results: A total of 11,710 IVIs were performed during the study period. Group A: A total of 8,647 IVIs performed including 2,041 ranibizumab, 6,169 bevacizumab, and 437 triamcinolone acetonide. The diagnosis included neovascular age-related macular degeneration (5,376), diabetic macular edema (1,587), retinal vein occlusion (1,068), and miscellaneous diagnosis (616). Group B: A total of 3,063 IVIs performed including 683 ranibizumab, 2,364 bevacizumab, and 16 triamcinolone acetonide. The diagnosis included neovascular age-related macular degeneration (1,836), diabetic macular edema (771), retinal vein occlusion (189), and miscellaneous diagnosis (267). A total of 5 cases (0.043%) of clinically suspected endophthalmitis occurred in 11,710 injections. Three cases (0.035%) occurred in Group A, and 2 cases (0.065%) occurred in Group B. Conclusion: The rate of clinically suspected endophthalmitis after IVIs is low whether the procedure is performed in the office or operating room setting. The findings have implications in terms of the patient convenience, efficiency, and cost of administrating these treatments.

Original languageEnglish
Pages (from-to)18-23
Number of pages6
JournalRetina
Volume34
Issue number1
DOIs
StatePublished - Jan 1 2014

Fingerprint

Intravitreal Injections
Endophthalmitis
Operating Rooms
Triamcinolone Acetonide
Retinal Vein Occlusion
Macular Edema
Macular Degeneration
Health Care Costs
Physicians
Injections
Ranibizumab
Bevacizumab

Keywords

  • Age-related macular degeneration
  • Bevacizumab
  • Diabetic retinopathy
  • Endophthalmitis
  • Intravitreal injection
  • Macular edema
  • Ranibizumab
  • Retinal vein occlusion
  • Triamcinolone

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Endophthalmitis associated with intravitreal injections : Office-based setting and operating room setting. / Tabandeh, Homayoun; Boscia, Francesco; Sborgia, Alessandra; Ciracì, Lorenza; Dayani, Pouya; Mariotti, Cesare; Furino, Claudio; Flynn, Harry W.

In: Retina, Vol. 34, No. 1, 01.01.2014, p. 18-23.

Research output: Contribution to journalArticle

Tabandeh, H, Boscia, F, Sborgia, A, Ciracì, L, Dayani, P, Mariotti, C, Furino, C & Flynn, HW 2014, 'Endophthalmitis associated with intravitreal injections: Office-based setting and operating room setting', Retina, vol. 34, no. 1, pp. 18-23. https://doi.org/10.1097/IAE.0000000000000008
Tabandeh, Homayoun ; Boscia, Francesco ; Sborgia, Alessandra ; Ciracì, Lorenza ; Dayani, Pouya ; Mariotti, Cesare ; Furino, Claudio ; Flynn, Harry W. / Endophthalmitis associated with intravitreal injections : Office-based setting and operating room setting. In: Retina. 2014 ; Vol. 34, No. 1. pp. 18-23.
@article{43a79f2904c3471d9fceb1ca9ee79a78,
title = "Endophthalmitis associated with intravitreal injections: Office-based setting and operating room setting",
abstract = "Purpose: To report on the occurrence of endophthalmitis after intravitreal injections (IVI) in two different settings: office-based and operating room. Methods: Consecutive case series. Retrospective review of all patients who underwent IVI by 2 physicians between January 2009 and December 2011. Group A underwent IVI in the examination room in office-based setting and Group B underwent IVI in the operating room. Results: A total of 11,710 IVIs were performed during the study period. Group A: A total of 8,647 IVIs performed including 2,041 ranibizumab, 6,169 bevacizumab, and 437 triamcinolone acetonide. The diagnosis included neovascular age-related macular degeneration (5,376), diabetic macular edema (1,587), retinal vein occlusion (1,068), and miscellaneous diagnosis (616). Group B: A total of 3,063 IVIs performed including 683 ranibizumab, 2,364 bevacizumab, and 16 triamcinolone acetonide. The diagnosis included neovascular age-related macular degeneration (1,836), diabetic macular edema (771), retinal vein occlusion (189), and miscellaneous diagnosis (267). A total of 5 cases (0.043{\%}) of clinically suspected endophthalmitis occurred in 11,710 injections. Three cases (0.035{\%}) occurred in Group A, and 2 cases (0.065{\%}) occurred in Group B. Conclusion: The rate of clinically suspected endophthalmitis after IVIs is low whether the procedure is performed in the office or operating room setting. The findings have implications in terms of the patient convenience, efficiency, and cost of administrating these treatments.",
keywords = "Age-related macular degeneration, Bevacizumab, Diabetic retinopathy, Endophthalmitis, Intravitreal injection, Macular edema, Ranibizumab, Retinal vein occlusion, Triamcinolone",
author = "Homayoun Tabandeh and Francesco Boscia and Alessandra Sborgia and Lorenza Cirac{\`i} and Pouya Dayani and Cesare Mariotti and Claudio Furino and Flynn, {Harry W}",
year = "2014",
month = "1",
day = "1",
doi = "10.1097/IAE.0000000000000008",
language = "English",
volume = "34",
pages = "18--23",
journal = "Retina",
issn = "0275-004X",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Endophthalmitis associated with intravitreal injections

T2 - Office-based setting and operating room setting

AU - Tabandeh, Homayoun

AU - Boscia, Francesco

AU - Sborgia, Alessandra

AU - Ciracì, Lorenza

AU - Dayani, Pouya

AU - Mariotti, Cesare

AU - Furino, Claudio

AU - Flynn, Harry W

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Purpose: To report on the occurrence of endophthalmitis after intravitreal injections (IVI) in two different settings: office-based and operating room. Methods: Consecutive case series. Retrospective review of all patients who underwent IVI by 2 physicians between January 2009 and December 2011. Group A underwent IVI in the examination room in office-based setting and Group B underwent IVI in the operating room. Results: A total of 11,710 IVIs were performed during the study period. Group A: A total of 8,647 IVIs performed including 2,041 ranibizumab, 6,169 bevacizumab, and 437 triamcinolone acetonide. The diagnosis included neovascular age-related macular degeneration (5,376), diabetic macular edema (1,587), retinal vein occlusion (1,068), and miscellaneous diagnosis (616). Group B: A total of 3,063 IVIs performed including 683 ranibizumab, 2,364 bevacizumab, and 16 triamcinolone acetonide. The diagnosis included neovascular age-related macular degeneration (1,836), diabetic macular edema (771), retinal vein occlusion (189), and miscellaneous diagnosis (267). A total of 5 cases (0.043%) of clinically suspected endophthalmitis occurred in 11,710 injections. Three cases (0.035%) occurred in Group A, and 2 cases (0.065%) occurred in Group B. Conclusion: The rate of clinically suspected endophthalmitis after IVIs is low whether the procedure is performed in the office or operating room setting. The findings have implications in terms of the patient convenience, efficiency, and cost of administrating these treatments.

AB - Purpose: To report on the occurrence of endophthalmitis after intravitreal injections (IVI) in two different settings: office-based and operating room. Methods: Consecutive case series. Retrospective review of all patients who underwent IVI by 2 physicians between January 2009 and December 2011. Group A underwent IVI in the examination room in office-based setting and Group B underwent IVI in the operating room. Results: A total of 11,710 IVIs were performed during the study period. Group A: A total of 8,647 IVIs performed including 2,041 ranibizumab, 6,169 bevacizumab, and 437 triamcinolone acetonide. The diagnosis included neovascular age-related macular degeneration (5,376), diabetic macular edema (1,587), retinal vein occlusion (1,068), and miscellaneous diagnosis (616). Group B: A total of 3,063 IVIs performed including 683 ranibizumab, 2,364 bevacizumab, and 16 triamcinolone acetonide. The diagnosis included neovascular age-related macular degeneration (1,836), diabetic macular edema (771), retinal vein occlusion (189), and miscellaneous diagnosis (267). A total of 5 cases (0.043%) of clinically suspected endophthalmitis occurred in 11,710 injections. Three cases (0.035%) occurred in Group A, and 2 cases (0.065%) occurred in Group B. Conclusion: The rate of clinically suspected endophthalmitis after IVIs is low whether the procedure is performed in the office or operating room setting. The findings have implications in terms of the patient convenience, efficiency, and cost of administrating these treatments.

KW - Age-related macular degeneration

KW - Bevacizumab

KW - Diabetic retinopathy

KW - Endophthalmitis

KW - Intravitreal injection

KW - Macular edema

KW - Ranibizumab

KW - Retinal vein occlusion

KW - Triamcinolone

UR - http://www.scopus.com/inward/record.url?scp=84891846451&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891846451&partnerID=8YFLogxK

U2 - 10.1097/IAE.0000000000000008

DO - 10.1097/IAE.0000000000000008

M3 - Article

C2 - 24362413

AN - SCOPUS:84891846451

VL - 34

SP - 18

EP - 23

JO - Retina

JF - Retina

SN - 0275-004X

IS - 1

ER -